埃克迪斯特和高强度间歇训练减轻老鼠阿尔茨海默氏症病理:对抑郁症,突触可塑性和神经炎症的影响
Parsa Gholipour1,2, Alireza Komaki3, Hesam Parsa4
1Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. parsagholipour1996@gmail.com.
Molecular neurobiology
|July 7, 2025
概括
这项研究表明,结合Ecdysterone和高强度间歇训练 (HIIT) 可以显著降低阿尔茨海默氏症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动生理学 运动生理学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 积累,导致神经炎症和突触可塑性受损.
- 抑郁症是阿尔茨海默病中常见的并发症,加剧了认知能力下降.
研究的目的:
- 调查埃克迪斯特和高强度间歇训练 (HIIT) 的治疗潜力,单独或组合,对Aβ诱导的阿尔茨海默病在老鼠模型中的进展.
- 评估这些干预措施对类似抑郁的行为,突触功能,神经炎症和Aβ斑块负担的影响.
主要方法:
- 大鼠接受了Aβ的管理,随后为期8周的Ecdysterone (10 mg/kg/day) 和/或HIIT.
- 使用行为测试 (强迫游泳测试),电生理记录 (长期强化),对Aβ斑块进行刚果红色染色以及对神经炎症标志物的量化.
主要成果:
- 服用Aβ诱导了类似抑郁症的行为,突触功能障碍,炎症和Aβ积累.
- 埃克迪斯特和HIIT都单独提供了部分保护.
- 埃克迪斯特和HIIT的组合在改善抑郁行为,恢复突触功能,减少神经炎症和降低海马和大脑皮层中的Aβ负担方面表现出显著更大的有效性.
结论:
- 结合Ecdysterone和HIIT治疗为缓解Aβ诱导的阿尔茨海默氏症病理和相关的抑郁类行为提供了一个强大的治疗策略.
- 协同效应可能源于突触功能改善,神经炎症减少和抑制Aβ斑块形成.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.粉样蛋白-β (Aβ) 是一种抑郁症 抑郁症 抑郁症埃克迪斯特 (Ecdy) 是一种高强度间歇训练 (HIIT) 是指高强度的间歇训练.长期增强 (LTP) 的作用.神经炎症是一种神经炎症.更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.3K
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
